China Forum III

  • China Forum III Banner

    China Forum III: Executing Joint Ventures in China: Structuring the Optimal Relationship

    China Forum’s I and II educated attendees on the issues for emerging healthcare companies to approach relationships in China. Forum III will provide a tactical approach innovative joint venture structures that provide maximum benefit to a technology company and investors.

    View the press release here, covering a series of unique case studies on the specifics of medical technology joint ventures in China.

    View the China Forum III panelists and advisors:

    • David Chen – Managing Director, BFC Partners
    • Dr. Jie Liu D’Elia – Corporate Vice President of Business Development and Corporate Communications, President of Simcere of America
    • Jay Dong – General Manager, Asia Pacific Region, Cell Signaling Technology (CST), Inc., Vice Chairman of BayHelix
    • Phillip Groves – CEO, DAC Management
    • Landon G. Lack – CEO, China MedConnect
    • Dr. Bin Li – Managing Director & Senior Research Analyst, Greater China Healthcare Morgan Stanley
    • Yuwen Liu – CEO, BioBay
    • Peter Luo – Founder and CEO, Adagene
    • Dr. Alan Paau – Vice Provost and Executive Director, Cornell Center for Technology Enterprise & Commercialization, Cornell University
    • Hong Tan – Cofounder and CEO, ET Healthcare, Inc.
    • Dr. James Tong – Chief Financial Officer, Chief Business & Development Officer, Director, Tianyin Pharmaceuticals
    • Dr. May Wang – Senior Vice President, Business Development & Strategic Alliances, Hutchison MediPharma
    • Mark Xu – General Manager, Trout Group at Shanghai
    • Dr. Steve Yang – AstraZeneca, SVP, EMBU R&D
    • Dr. Jimmy Zhang – Leader, Merck China R&D and VC investment BD
    • Tony Zhang – Sr. Research Fellow, Eli Lily, and board member, BayHelix

     

    We will focus on the specifics of structuring and executing a joint venture by looking at two case studies involving Western healthcare company providing technology and with the Chinese partner providing the capital and distribution. One theoretical approach considered:

    • Chinese Investors take minority position in US company and majority position of newly formed Chinese company (NewCo).
    • US company receives equity investment in exchange for technology provided to NewCo.
    • US company receives minority investment position new NewCo and ongoing royalty stream for ongoing consulting services.
    • NewCo executive/investors take role in US company.

    The approach provides what both parties seek. In the case of US, capital to grow its US market, royalties or sales an expanded market in china. Chinese partner gains technology and expertise to grow and a minority position in US company.

    We will consider the financial, regulatory and tax implications, as well as legal structures for creating a new operating company jointly owned by Chinese investors, Chinese operators and US companies. We will examine the currency, Tax, Financial, immigration issues for all involved. Such questions as:

    • The opportunity for Chinese executives seeking US Citizenship a driver in gaining executive or ownership positions in US companies.
    • The issue of foreign currency exportation and conversion of foreign currency to US.
    • Legal, tax and regulatory issues. Hong Kong an intermediate headquarters.

    The session is also designed to begin conversation between US technology companies and Chinese partners. Attendees are targeted US companies seeking to explore a China strategy as well as Chinese investors and operating companies.

    Delegates will receive profiles of US companies seeking to expand into China as well. All will gain access to the conference partnering system to make connections.

    Date: Monday, January 7th, 2013

    Location: Sir Francis Drake Hotel, San Francisco

    Audience: Institutional investors, high net worth individual investors, family offices, business development executives throughout the US and Europe building and financing high growth medical technology, health care and life science companies.

    Format

    1:00pm Call to order and outlook on China from Morgan Stanley analyst Bin Li

    1:15 – 2:00 Panel One case study discussion

    2:00 – 2:45 Panel Two case study discussion

    2:30pm Case Study 2. Comments and discussion by panel of experts

    2:45 – Break

    3:00 – Brief presentation on China Opportunity. Yuwen Liu, CEO BioBay

    3:15 – Panel Three case study discussion

    4:00 – End session. Reception.

    For sponsorship and speaking inquiries and general questions, please contact Tatiana Ridley, Program Manager, China Forum III at tridley@onemedplace.com.

     

  • Conference Info:

     

    Date: June 26-27, 2013
    Location: The Metropolitan Club, New York City


    Audience: Institutional investors, high net worth individual investors, family offices, business development executives throughout the US and Europe building and financing high growth medical technology, health care and life science companies.

    View the Schedule!

    View the Agenda!